← Back to home

REFRACTORY B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DLBCL AND CLASSIC HL

Clinical trials for REFRACTORY B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DLBCL AND CLASSIC HL explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DLBCL AND CLASSIC HL trials appear

Sign up with your email to follow new studies for REFRACTORY B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DLBCL AND CLASSIC HL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Early trial tests new Two-Drug attack on Tough-to-Treat blood cancers

Disease control Ongoing

This early-stage study is testing a combination of two drugs, pembrolizumab and vorinostat, for patients with certain types of lymphoma that have come back or stopped responding to previous treatments. The main goals are to find the safest dose and understand the side effects of …

Matched conditions: REFRACTORY B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DLBCL AND CLASSIC HL

Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control

Last updated Mar 30, 2026 14:28 UTC

REFRACTORY B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DLBCL AND CLASSIC HL

Get alerted when new REFRACTORY B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DLBCL AND CLASSIC HL trials appear

Early trial tests new Two-Drug attack on Tough-to-Treat blood cancers